KR20220100992A - 브루톤 티로신 키나제 억제제의 투여 - Google Patents
브루톤 티로신 키나제 억제제의 투여 Download PDFInfo
- Publication number
- KR20220100992A KR20220100992A KR1020227022407A KR20227022407A KR20220100992A KR 20220100992 A KR20220100992 A KR 20220100992A KR 1020227022407 A KR1020227022407 A KR 1020227022407A KR 20227022407 A KR20227022407 A KR 20227022407A KR 20220100992 A KR20220100992 A KR 20220100992A
- Authority
- KR
- South Korea
- Prior art keywords
- day
- cycle
- days
- administered
- btk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020237028538A KR20230127372A (ko) | 2019-12-06 | 2020-12-03 | 브루톤 티로신 키나제 억제제의 투여 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944674P | 2019-12-06 | 2019-12-06 | |
| US62/944,674 | 2019-12-06 | ||
| US202063077996P | 2020-09-14 | 2020-09-14 | |
| US63/077,996 | 2020-09-14 | ||
| US202063109698P | 2020-11-04 | 2020-11-04 | |
| US63/109,698 | 2020-11-04 | ||
| PCT/US2020/063089 WO2021113497A1 (en) | 2019-12-06 | 2020-12-03 | Dosing of a bruton's tyrosine kinase inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237028538A Division KR20230127372A (ko) | 2019-12-06 | 2020-12-03 | 브루톤 티로신 키나제 억제제의 투여 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220100992A true KR20220100992A (ko) | 2022-07-18 |
Family
ID=73854977
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227022407A Ceased KR20220100992A (ko) | 2019-12-06 | 2020-12-03 | 브루톤 티로신 키나제 억제제의 투여 |
| KR1020237028538A Pending KR20230127372A (ko) | 2019-12-06 | 2020-12-03 | 브루톤 티로신 키나제 억제제의 투여 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237028538A Pending KR20230127372A (ko) | 2019-12-06 | 2020-12-03 | 브루톤 티로신 키나제 억제제의 투여 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12551463B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4069219A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7142173B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20220100992A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115175677A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020397034B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022009716A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292882B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022006631A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021113497A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3108065C (en) | 2018-07-31 | 2025-10-07 | Loxo Oncology, Inc. | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| KR20220100992A (ko) * | 2019-12-06 | 2022-07-18 | 록쏘 온콜로지, 인코포레이티드 | 브루톤 티로신 키나제 억제제의 투여 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| US20150291554A1 (en) | 2012-11-02 | 2015-10-15 | Pfizer Inc. | Bruton's Tyrosine Kinase Inhibitors |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| CN114605327B (zh) * | 2015-12-16 | 2025-03-11 | 洛克索肿瘤学股份有限公司 | 可用作激酶抑制剂的化合物 |
| WO2017132474A1 (en) | 2016-01-30 | 2017-08-03 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| KR102376764B1 (ko) | 2016-08-05 | 2022-03-18 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물 |
| CN110177788B (zh) | 2017-01-07 | 2023-03-24 | 重庆复创医药研究有限公司 | 作为bcl-2选择性凋亡诱导剂的化合物 |
| SI3612531T1 (sl) | 2017-04-18 | 2022-11-30 | Shanghai Fochon Pharmaceutical Co., Ltd. | Sredstva, ki sprožajo apoptozo |
| JP2020528061A (ja) | 2017-07-26 | 2020-09-17 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | BET阻害剤、Bcl−2阻害剤及び抗CD20抗体を用いた併用療法 |
| IL316472A (en) | 2018-01-10 | 2024-12-01 | Recurium Ip Holdings Llc | Benzamide compounds |
| CN112437772B (zh) | 2018-04-29 | 2023-11-21 | 百济神州有限公司 | Bcl-2抑制剂 |
| CA3108065C (en) | 2018-07-31 | 2025-10-07 | Loxo Oncology, Inc. | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| KR20220100992A (ko) * | 2019-12-06 | 2022-07-18 | 록쏘 온콜로지, 인코포레이티드 | 브루톤 티로신 키나제 억제제의 투여 |
-
2020
- 2020-12-03 KR KR1020227022407A patent/KR20220100992A/ko not_active Ceased
- 2020-12-03 US US17/782,758 patent/US12551463B2/en active Active
- 2020-12-03 KR KR1020237028538A patent/KR20230127372A/ko active Pending
- 2020-12-03 CN CN202080095816.0A patent/CN115175677A/zh active Pending
- 2020-12-03 IL IL292882A patent/IL292882B1/en unknown
- 2020-12-03 JP JP2021557408A patent/JP7142173B2/ja active Active
- 2020-12-03 EP EP20825385.6A patent/EP4069219A1/en active Pending
- 2020-12-03 AU AU2020397034A patent/AU2020397034B2/en active Active
- 2020-12-03 WO PCT/US2020/063089 patent/WO2021113497A1/en not_active Ceased
- 2020-12-03 MX MX2022006631A patent/MX2022006631A/es unknown
- 2020-12-03 BR BR112022009716A patent/BR112022009716A2/pt unknown
-
2022
- 2022-09-12 JP JP2022144243A patent/JP7654604B2/ja active Active
-
2024
- 2024-02-26 AU AU2024201263A patent/AU2024201263B2/en active Active
-
2025
- 2025-03-19 JP JP2025044178A patent/JP2025098099A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4069219A1 (en) | 2022-10-12 |
| KR20230127372A (ko) | 2023-08-31 |
| CN115175677A (zh) | 2022-10-11 |
| AU2024201263B2 (en) | 2025-05-01 |
| JP2022177119A (ja) | 2022-11-30 |
| IL292882B1 (en) | 2026-05-01 |
| US12551463B2 (en) | 2026-02-17 |
| AU2020397034A1 (en) | 2022-07-21 |
| AU2024201263A1 (en) | 2024-03-14 |
| BR112022009716A2 (pt) | 2022-08-09 |
| IL292882A (en) | 2022-07-01 |
| JP2025098099A (ja) | 2025-07-01 |
| NZ788615A (en) | 2024-10-25 |
| CA3160417A1 (en) | 2021-06-10 |
| US20230041515A1 (en) | 2023-02-09 |
| MX2022006631A (es) | 2022-09-07 |
| AU2020397034B2 (en) | 2023-12-07 |
| JP7142173B2 (ja) | 2022-09-26 |
| JP7654604B2 (ja) | 2025-04-01 |
| WO2021113497A1 (en) | 2021-06-10 |
| JP2022518974A (ja) | 2022-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3458091B1 (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| US20230107195A1 (en) | Treatment of cancer with smg1-inhibitors | |
| US20170306050A1 (en) | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases | |
| CN110325191A (zh) | 以较少的副作用治疗egfr-驱动的癌症 | |
| UA125216C2 (uk) | Комбінована терапія | |
| US20160287588A1 (en) | Methods of treating a bruton's tyrosine kinase disease or disorder | |
| AU2024201263B2 (en) | Dosing of a Bruton's Tyrosine Kinase inhibitor | |
| CA3107023A1 (en) | Ep4 inhibitors and synthesis thereof | |
| JP2016522247A (ja) | 組合せ医薬 | |
| KR20210106483A (ko) | Mdm2 억제제를 위한 확장된 저용량 요법 | |
| WO2021207598A1 (en) | Combination treatment with an agonist of p53 and a second therapeutic agent | |
| JP5393691B2 (ja) | 急性ヒト骨髄性白血病細胞を死滅させるトロンボポエチン受容体作用薬(TpoRA) | |
| CN101969947B (zh) | 使用诸如呋咯地辛的pnp抑制剂与烷化剂或抗cd20剂的组合治疗血液学癌症的方法 | |
| EP4504202B1 (en) | Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer | |
| CA3160417C (en) | Dosing of a bruton's tyrosine kinase inhibitor | |
| EA051944B1 (ru) | Введение доз ингибитора тирозинкиназы брутона | |
| EA046722B1 (ru) | Введение доз ингибитора тирозинкиназы брутона | |
| NZ788615A9 (en) | Dosing of a bruton's tyrosine kinase inhibitor | |
| AU2012321091B2 (en) | Methods of treating a Bruton's Tyrosine Kinase disease or disorder | |
| HK40004756A (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| HK40004756B (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| PA0105 | International application |
Patent event date: 20220630 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220630 Comment text: Request for Examination of Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20220630 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230119 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20230527 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20230119 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20230822 |